Tyra Biosciences Reports $700.5M Cash Balance and Initial SURF302 Results
Tyra Biosciences reported positive initial Phase 2 results for oral dabogratinib in FGFR3-altered bladder cancer and announced a strengthening of its balance sheet following a $400 million financing.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed